List of Excipients in Branded Drug GEMCITABINE HYDROCHLORIDE

Generic Drugs Containing GEMCITABINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	gemcitabine hydrochloride	16729-092	MANNITOL
Accord Healthcare Inc	gemcitabine hydrochloride	16729-092	SODIUM ACETATE
Actavis Pharma Inc	gemcitabine hydrochloride	45963-612	MANNITOL
Actavis Pharma Inc	gemcitabine hydrochloride	45963-612	SODIUM ACETATE
Actavis Pharma Inc	gemcitabine hydrochloride	45963-612	SODIUM HYDROXIDE
Mylan Institutional LLC	gemcitabine hydrochloride	67457-464	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in GEMCITABINE HYDROCHLORIDE?

# Of NDCs	Excipient
4	HYDROCHLORIC ACID
7	MANNITOL
6	SODIUM ACETATE
5	SODIUM HYDROXIDE

Gemcitabine Hydrochloride Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 10, 2026

Gemcitabine hydrochloride is an established generic cytotoxic nucleoside analogue with limited composition-of-matter protection and intense injectable competition. The strongest commercial opportunities are not in a conventional aqueous vial alone. They are in reducing reconstitution burden, improving stability, lowering occupational exposure, extending administration intervals, enabling local delivery, and combining gemcitabine with delivery technologies that create new patentable claims.

The most attractive excipient strategies are:

1. Ready-to-use or extended-stability aqueous injections.
2. Lyophilized products with faster reconstitution and lower vial waste.
3. Liposomal, polymeric, albumin-based, or depot formulations.
4. Intravesical, intraperitoneal, pulmonary, and tumor-localized delivery.
5. Combination products that improve tumor exposure while reducing systemic toxicity.
6. Excipient systems that support manufacturing, scale-up, and differentiated regulatory filings.

Gemcitabine is commercially mature as an active pharmaceutical ingredient, but its delivery platform remains open to product and process innovation.

What is gemcitabine hydrochloride and how is it administered?

Gemcitabine hydrochloride is the hydrochloride salt of gemcitabine, a deoxycytidine analogue used primarily in oncology. FDA-approved indications have included pancreatic cancer, non-small-cell lung cancer, breast cancer, ovarian cancer, and bladder cancer, either as monotherapy or in combination regimens depending on the indication and product labeling.[1]

The principal commercial dosage form is a sterile intravenous solution or lyophilized powder requiring reconstitution. Gemcitabine is generally administered by intravenous infusion, with dosing schedules determined by tumor type and combination therapy.

Attribute	Commercial relevance
Active ingredient	Gemcitabine hydrochloride
Therapeutic class	Antimetabolite; nucleoside analogue
Primary route	Intravenous infusion
Common dosage forms	Lyophilized powder; sterile solution
Main clinical constraint	Short systemic half-life and dose-limiting toxicity
Main formulation challenge	Aqueous stability, reconstitution, handling safety, and exposure control
Generic status	Mature, multisource injectable market
Key opportunity	Delivery-system differentiation rather than new-molecule protection

Gemcitabine has a short plasma half-life because it is rapidly metabolized by cytidine deaminase. Its active metabolites are intracellular, while systemic exposure can produce myelosuppression, hepatic toxicity, pulmonary toxicity, and other adverse effects. This pharmacology creates a commercial rationale for formulations that alter distribution, prolong exposure, or increase tumor selectivity.

What excipients are used in gemcitabine hydrochloride injections?

Conventional gemcitabine hydrochloride injections use a limited excipient profile. The most important formulation variables are pH, tonicity, buffer capacity, concentration, container compatibility, and stability during storage and administration.

Typical excipient categories include:

Excipient category	Examples	Commercial function
Tonicity agents	Sodium chloride, dextrose	Isotonicity and infusion compatibility
pH adjusters	Hydrochloric acid, sodium hydroxide	pH control
Buffers	Citrate, phosphate, acetate systems	pH maintenance, if compatible
Bulking agents	Mannitol, sucrose, lactose	Lyophilized cake structure
Stabilizers	Sugars, polyols, amino acids	Protection during drying and storage
Surfactants	Polysorbate 20, polysorbate 80, poloxamers	Interfacial protection in complex systems
Chelators	EDTA or related agents	Metal-ion control where justified
Permeation or penetration enhancers	Formulation-dependent	Local or mucosal delivery
Lipid excipients	Phospholipids, cholesterol, triglycerides	Liposomes, emulsions, or lipid nanoparticles
Polymer excipients	PLGA, PEG derivatives, chitosan, hyaluronic acid	Sustained release, targeting, or depot delivery

The current label for Gemzar described gemcitabine hydrochloride as a sterile lyophilized product requiring reconstitution with preservative-free normal saline. The reconstituted solution has concentration, storage, and handling requirements that affect pharmacy workflow and product differentiation.[2]

A manufacturer should avoid unnecessary excipients in a conventional generic because each added component creates new extractables, leachables, compatibility, toxicity, and regulatory burdens. A simple formulation with a clear stability advantage is more commercially defensible than a complex excipient package without measurable clinical or operational benefit.

What formulation excipients are best suited to gemcitabine hydrochloride?

The best excipient strategy depends on the intended product category.

Conventional injectable formulation

For an immediate-release intravenous product, the preferred strategy is a low-complexity formulation that improves:

• Reconstitution time.
• Powder cake integrity.
• Solution clarity.
• Vial stability.
• Dilution compatibility.
• Protection from light or oxygen.
• Reduced adsorption to infusion materials.
• Manufacturing yield.

Mannitol or sucrose may support lyophilized cake formation and protect the active ingredient during freeze-drying. However, the choice must be supported by solid-state, reconstitution, and long-term stability data. Surfactants are more relevant when the formulation has a demonstrated adsorption or interfacial instability problem.

Ready-to-use liquid injection

A ready-to-use solution can remove the reconstitution step and reduce pharmacy labor. The commercial value is highest in hospitals and oncology centers with high chemotherapy throughput.

Potential excipient approaches include:

• Low-concentration isotonic saline systems.
• Controlled-pH aqueous vehicles.
• Oxygen-reduced headspace.
• Low-sorption container closure systems.
• Polymer bags or vials with demonstrated compatibility.
• Stabilizer combinations that preserve potency during refrigerated storage.

The commercial barrier is stability. A ready-to-use product must demonstrate acceptable potency, impurity control, particulate limits, container compatibility, and in-use stability. If the product requires a short shelf life, cold-chain costs may eliminate the operational advantage.

Liposomal gemcitabine

Liposomal delivery is one of the most commercially visible opportunities. Phospholipids, cholesterol, and PEG-lipids can alter distribution and prolong circulation. A liposomal gemcitabine product may seek higher tumor exposure or lower exposure in normal tissues.

The patent opportunity is usually concentrated in:

• Lipid composition.
• Particle size and size distribution.
• Encapsulation efficiency.
• Drug-to-lipid ratio.
• Release profile.
• Surface charge.
• PEG density.
• Manufacturing process.
• Use in a defined cancer indication.

A liposomal product faces complex analytical requirements. The sponsor must characterize free versus encapsulated gemcitabine, leakage, particle size, morphology, release, sterility, and batch reproducibility. These requirements raise development cost but also make rapid generic substitution more difficult.

Polymer-based sustained-release systems

PLGA microspheres, injectable depots, hydrogels, and implantable systems can extend gemcitabine release. These systems are relevant to localized treatment of solid tumors, intraperitoneal administration, and postoperative delivery.

The key technical problems are gemcitabine’s hydrophilicity and burst release. Polymer systems may require ion pairing, complexation, encapsulation aids, or chemically modified prodrug approaches. A product based on a new gemcitabine derivative may fall outside a conventional 505(b)(2) formulation strategy and require a more extensive development package.

Potential patent claims include:

• Polymer molecular weight and composition.
• Particle dimensions.
• Drug loading.
• Release kinetics.
• Injection-site tolerability.
• Combination with surgery, radiation, or immunotherapy.
• Local administration methods.

Mucoadhesive and local-delivery excipients

Chitosan, hyaluronic acid, thermosensitive polymers, and bioadhesive systems can support intravesical, intraperitoneal, pulmonary, or intratumoral delivery. These excipients may increase residence time and reduce systemic exposure.

For bladder cancer, intravesical delivery is commercially attractive because conventional drug washout limits exposure. A mucoadhesive gemcitabine system could create claims around retention time, dosing frequency, tumor contact, and combination with device-based delivery.

For pancreatic cancer, intraperitoneal or tumor-localized delivery may address the difficulty of achieving adequate local concentrations. The clinical and regulatory burden is higher because the product may be treated as a complex drug-device or combination product depending on the delivery system.

What patents protect gemcitabine hydrochloride formulations?

Gemcitabine’s original composition-of-matter protection has expired. The principal commercial protection now lies in formulation, delivery, manufacturing, combination, and method-of-use claims.

The original gemcitabine patent family is associated with Eli Lilly and related inventors. U.S. Patent No. 5,464,826 covered difluorodeoxycytidine compounds, including gemcitabine, but its effective commercial life has ended.[3]

Protection layer	Current commercial significance
Composition of matter	Expired
Conventional injectable formulation	Generally weak unless a specific improvement is claimed
Lyophilization process	Potentially relevant if tied to stability or manufacturing advantages
Liposomal delivery	Stronger potential if composition and performance are narrow
Polymer depot	Stronger potential, particularly with release and local-use claims
Combination therapy	Potentially valuable but vulnerable to obviousness and written-description challenges
Method of use	Relevant where a new dosing schedule or patient population is supported
Manufacturing process	Commercially useful if it improves yield, impurity profile, or scale-up
Device-enabled administration	Potentially strong when integrated with a delivery platform

Patent strength depends on claim scope, priority date, prosecution history, enablement, and whether the formulation produces an unexpected pharmacokinetic or clinical result. A claim that merely substitutes one conventional sugar, buffer, or surfactant for another is often more vulnerable than a claim tied to a defined release profile or clinically demonstrated benefit.

What is the Orange Book status of gemcitabine hydrochloride?

Gemcitabine hydrochloride is a generic injectable product with no meaningful remaining composition-of-matter exclusivity. The original Gemzar product had FDA approval and later faced generic competition after patent and regulatory protections expired.

For a specific abbreviated new drug application, Orange Book analysis should focus on:

• Whether the reference listed drug has active listed patents.
• Whether a generic applicant must make a Paragraph IV certification.
• Whether any method-of-use patent is listed against a relevant indication.
• Whether the proposed label carves out a patented use.
• Whether the product is an injectable solution or lyophilized dosage form.
• Whether the applicant relies on a reference listed drug with current marketing status.

A conventional gemcitabine hydrochloride ANDA normally faces a low patent barrier because the molecule and established injectable use are old. A novel formulation may instead use a 505(b)(2) pathway if it changes the dosage form, route, release profile, or clinical use and relies partly on published literature or an FDA-approved product.[4]

When does gemcitabine lose exclusivity and what generic entry risks exist?

Gemcitabine has already lost practical exclusivity in the United States and other major markets. Generic entry risk is therefore high for standard immediate-release injectable products.

The risk profile differs by product type:

Product type	Generic entry risk	Main barrier
Standard lyophilized vial	High	Low formulation complexity
Standard aqueous injection	High	Established manufacturing and clinical use
Ready-to-use bag	Moderate	Stability and container compatibility
Liposomal formulation	Moderate to low initially	Complex characterization and formulation patents
PLGA depot	Low initially	Clinical bridging and manufacturing complexity
Intravesical mucoadhesive product	Low to moderate	New route, device, and clinical claims
Targeted nanoparticle	Low initially	Platform, analytics, and clinical development
Combination product	Depends on claims	Product-specific patent and regulatory strategy

A standard generic launch can compete primarily on price, shortage resilience, vial sizes, contract manufacturing capacity, and hospital purchasing relationships. A differentiated product must justify a premium through measurable savings or clinical value.

Which companies compete in the gemcitabine hydrochloride market?

Competition includes branded historical suppliers, generic injectable manufacturers, specialty oncology companies, contract manufacturers, and developers of delivery platforms.

Relevant competitive groups include:

• Large generic manufacturers with sterile injectable capacity.
• Regional oncology suppliers.
• Contract development and manufacturing organizations.
• Liposomal drug-delivery companies.
• Nanoparticle and polymer-depot developers.
• Hospital-oriented ready-to-administer product companies.
• Firms developing combination regimens involving gemcitabine.

The commercial market is fragmented by geography. The United States emphasizes FDA-approved injectable supply and group purchasing contracts. Europe is influenced by national tenders and hospital procurement. Emerging markets place greater weight on price, local manufacturing, and supply continuity.

A company without sterile injectable infrastructure may pursue licensing or co-development with a CDMO. The most valuable partner assets are aseptic filling, lyophilization, oncology handling expertise, container-closure testing, and regulatory experience with complex injectables.

What licensing deals and commercial partnerships are available?

Licensing opportunities are strongest where the partner owns a delivery platform rather than a conventional gemcitabine product. Potential deal structures include:

• Regional rights to a liposomal or depot formulation.
• Co-development of a 505(b)(2) product.
• Supply agreements for sterile gemcitabine hydrochloride.
• Technology licenses for nanoparticle manufacture.
• Combination-product development with an oncology therapy.
• Hospital-channel commercialization rights.
• Co-promotion agreements for ready-to-use oncology products.

A typical diligence review should examine whether the licensed technology has:

• Issued composition claims.
• Patent term extending beyond launch.
• Freedom to operate for the selected excipients.
• Scalable manufacturing.
• Defined clinical differentiation.
• A realistic regulatory pathway.
• Exclusivity against competing gemcitabine delivery systems.

A platform patent with no gemcitabine-specific claims may provide limited blocking power. Conversely, a narrow gemcitabine formulation patent may be easier to enforce but may not support a large market if physicians and hospitals can substitute conventional gemcitabine.

What manufacturing and intellectual-property barriers affect gemcitabine formulations?

Sterile manufacturing is a more immediate barrier than active-ingredient availability. The major operational risks include:

• Aseptic processing failures.
• Gemcitabine occupational exposure.
• Cross-contamination in multiproduct facilities.
• Lyophilization cycle variability.
• Particulate formation.
• Adsorption to bags, tubing, and filters.
• Container-closure extractables and leachables.
• Limited stability after reconstitution.
• High-cost low-volume presentations.
• Supply interruptions for specialized excipients.

Gemcitabine is a hazardous cytotoxic compound. Facilities require containment, validated cleaning procedures, appropriate personal protective equipment, and controls for handling powder and concentrated solutions. These requirements can favor established oncology injectable manufacturers.

For complex formulations, the analytical package may become the principal barrier. A liposomal or polymeric product requires more than potency and impurity testing. It may require particle characterization, encapsulation testing, release profiling, morphology analysis, and orthogonal methods for free and bound drug.

How does gemcitabine compare with competing cytotoxic drugs?

Gemcitabine competes with fluoropyrimidines, platinum agents, taxanes, irinotecan, and newer targeted or immune therapies. Its advantages are broad historical use, established clinical protocols, low active-ingredient cost, and compatibility with combination regimens.

Factor	Gemcitabine	Conventional cytotoxic competitors
Molecule maturity	High	Varies
Generic price pressure	High	High for older agents
Delivery innovation potential	High	Varies by molecule
Short half-life problem	Significant	Drug-specific
Combination use	Extensive	Extensive
Commercial differentiation	Requires formulation or service innovation	Often requires the same
Clinical switching risk	Moderate	Depends on regimen and indication

A differentiated gemcitabine formulation must compete against the low cost and clinical familiarity of standard gemcitabine. Improved pharmacokinetics alone may not be sufficient. The product should show a clinically meaningful improvement, reduced administration burden, lower toxicity, or better tumor exposure.

What are the most attractive commercial opportunities for gemcitabine excipients?

The strongest opportunities rank as follows:

1. Ready-to-use products that eliminate reconstitution.
2. Extended-stability bags or vials for oncology centers.
3. Localized delivery for bladder, pancreatic, or postoperative treatment.
4. Liposomal gemcitabine with a clinically validated exposure advantage.
5. Combination delivery systems that pair gemcitabine with a second active agent.
6. Low-volume, high-concentration products that reduce infusion time.
7. Safer handling systems that reduce occupational exposure.
8. Pediatric or geriatric formulations with improved dosing flexibility.

The least attractive opportunity is a conventional generic with a minor excipient substitution and no operational advantage. Such a product is unlikely to support durable pricing or strong patent protection.

Key Takeaways

• Gemcitabine hydrochloride is a mature generic oncology injectable with high competition.
• Composition-of-matter exclusivity has expired; commercial protection must come from formulation, delivery, manufacturing, or use claims.
• Simple excipient changes can improve stability but usually provide weak patent differentiation.
• Ready-to-use products can create value by reducing pharmacy labor and reconstitution risk.
• Liposomal, polymeric, mucoadhesive, and depot systems offer stronger patent and pricing potential.
• A 505(b)(2) strategy may be appropriate for a materially different dosage form, route, or release profile.
• Manufacturing capability, cytotoxic containment, sterile filling, and analytical complexity are major barriers.
• The strongest product candidates combine a measurable clinical benefit with a clear hospital workflow advantage.

FAQs About Gemcitabine Hydrochloride Excipient and Patent Strategy

Can polysorbate 80 be used in gemcitabine hydrochloride formulations?

Polysorbate 80 can be evaluated in complex delivery systems, particularly liposomal or nanoparticle formulations, but it is not automatically needed in a conventional aqueous gemcitabine injection. Its use requires compatibility, degradation, particulate, and safety assessment.

Can gemcitabine hydrochloride be formulated as an oral product?

Oral delivery is technically difficult because gemcitabine has limited gastrointestinal stability, poor absorption, and rapid metabolism. Oral products generally require permeability enhancement, prodrug chemistry, nanoparticle delivery, or enzyme-inhibition strategies.

Are gemcitabine formulation patents likely to block standard generics?

Usually not. Standard gemcitabine hydrochloride generics face limited formulation patent risk unless a listed patent specifically covers the proposed dosage form, formulation, or use.

Is a liposomal gemcitabine product eligible for automatic generic substitution?

Not necessarily. Differences in liposome composition, particle attributes, release, pharmacokinetics, and clinical performance can require a separate regulatory pathway and may prevent simple substitution with conventional gemcitabine.

What is the best excipient opportunity for a hospital-focused gemcitabine product?

A ready-to-use, extended-stability sterile product is the most direct hospital opportunity. Its value depends on validated shelf life, container compatibility, reduced preparation time, and reliable supply.

References

1. U.S. Food and Drug Administration. (2020). Gemzar (gemcitabine hydrochloride) prescribing information. FDA.

2. Eli Lilly and Company. (1996). Gemzar (gemcitabine hydrochloride) injection prescribing information. U.S. Food and Drug Administration.

3. U.S. Patent No. 5,464,826. (1995). Difluorodeoxycytidine compounds and pharmaceutical compositions. U.S. Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

6. National Library of Medicine. (2024). Gemcitabine hydrochloride drug information and labeling. DailyMed.